

**ANTI-INFLAMMATORY ACTIVITY OF *CRITONIA AROMATISANS* AND  
*MONTANOA GRANDIFLORA* LEAVES EXTRACTS, PLANTS USED IN  
MAYAN TRADITIONAL MEDICINE TO TREAT INFLAMMATION**

**ACTIVIDAD ANTIINFLAMATORIA DE EXTRACTOS DE HOJAS DE *CRITONIA  
AROMATISANS* Y *MONTANOA GRANDIFLORA*, PLANTAS UTILIZADAS EN  
LA MEDICINA TRADICIONAL MAYA PARA TRATAR LA INFLAMACIÓN**

Fabiola Villa-De la Torre 1,3; Ana María Puebla-Pérez 2; Victor Ermilo Arana-Argáez 3; Rolffy Ortiz-Andrade 3;  
Gregorio Carballo-Uicab 3; Martha Méndez-González 1; Mirbella Cáceres-Farfán 1; Rocío Borges Argáez 1\*

**Rocío Borges Argáez**

*Centro de Investigación Científica de Yucatán, Unidad de Biotecnología.*

Correo electrónico: [rborges@cicy.mx](mailto:rborges@cicy.mx)

**ABSTRACT**

The aim of the study is to investigate anti-inflammatory properties of polar and non-polar extracts prepared from *Critonia aromatisans* and *Montanoa grandiflora*, two common native species used in Mayan traditional ointments to treat inflammation, joint pain and rheumatism. The anti-inflammatory properties of methanol/acetonitrile and n-hexane leaf extracts were tested *in vivo* and *in vitro*. The extracts of *C. aromatisans* and *M. grandiflora* decreased in a concentration-dependent manner lipopolysaccharide (LPS)-induced nitric oxide (NO) production without affecting the cell viability. The extracts of *C. aromatisans* at dose of 200 mg/kg exhibited substantial anti-inflammatory activity in the carrageenan-induced paw oedema test and 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced ear oedema inhibition assay with a reduction in inflammation of up to 90 and 80%, respectively. These results validate the traditional uses by Mayan communities that endorse the use of this species to treat inflammation.

**Key words:** *Critonia aromatisans*, *Montanoa grandiflora*, inflammation, carrageenan, Nitric oxide, macrophages

**RESUMEN**

El objetivo del estudio es investigar las propiedades antiinflamatorias de extractos de *Critonia aromatisans* y *Montanoa grandiflora*, dos especies nativas comunes utilizadas en ungüentos tradicionales mayas para tratar la inflamación, dolor en las articulaciones y el reumatismo. Las propiedades antiinflamatorias de extractos metanol/acetonitrilo y n-hexánicos de hojas fueron evaluados *in vitro* e *in vivo*. Los extractos de *C. aromatisans* y *M. grandiflora* disminuyeron la producción de óxido nítrico (NO) inducida por LPS de manera dependiente de la concentración sin afectar la viabilidad celular. Los extractos de *C. aromatisans*, a dosis de 200 mg/kg exhiben actividad antiinflamatoria sustancial en el ensayo de edema plantar inducido por carragenina y en el ensayo de inhibición de edema de la oreja inducido por TPA con una reducción en la inflamación de 90 y 80%,

respectivamente. Estos resultados validan los usos tradicionales de las comunidades mayas que avalan el uso de esta especie para el tratamiento de la inflamación.

**Palabras clave:** *Critonia aromatisans*, *Montanoa grandiflora*, inflamación, carragenina, óxido nítrico, macrófagos.

## INTRODUCTION

In Yucatán, México, ancient Mayan knowledge has provided remedies for the treatment of diverse ailments, especially among rural populations. Inflammation is a response induced by pathogens, damaged tissue or autoimmune and inflammatory diseases. Physiologically, inflammation operates in a restricted environment to eradicate infected or devitalized tissue. Although usually beneficial to the host, inflammation is intrinsically destructive to the immediate surroundings (Ahmed *et al.*, 1995). Rheumatism is a term used to describe the inflammation or degeneration of the connective tissues of the body, and this condition affects primarily the muscles, joints and tendons, among other tissues. Rheumatism can also refer to the autoimmune disease that leads to the deformity of muscles or joints (joint destruction) (Zuther, 2009). Several molecules are involved in the inflammatory response, including prostaglandins and nitric oxide (NO) (Gallin and Snyderman 1999; Koeberle and Werz 2015). NO production by activated macrophages has been shown to mediate immune functions, including antimicrobial and antitumor activities. However, excess NO production has been implicated in inflammatory processes, septic shock, asthma and autoimmune diseases such rheumatoid arthritis (Mac Micking *et al.*, 1995; Jerzynska *et al.*, 2014).

Therefore, the inhibition of NO production has become a therapeutic target for the treatment of inflammatory diseases (Azadmehr, 2009; Wen-Jun. *et al.*, 2015).

Inflammation affects many people worldwide, and homemade remedies prepared from single plants or mixtures of plants are used in several cultures to treat these symptoms. Two common plants used in the Yucatán Peninsula to treat inflammation and rheumatism are *Critonia aromatisans* (DC.) R.M. King & H. Rob. and *Montanoa grandiflora* DC., members of the Asteraceae family. These plants are commonly used alone, together or in different plant mixtures to prepare anti-inflammatory and anti-arthritis remedies. *C. aromatisans* (formerly *Eupatorium hemipteropodum*) is known in Mexico as “Chiople” and in Cuba as “Trébol de olor”. Mayan people traditionally apply the leaves to the painful area; for example, the leaves are applied to the forehead to treat migraines. The leaves are also used to prepare decoctions to treat oedema and can be used as a poultice or in ointments elaborated with petrolatum (Méndez-González *et al.*, 2012). The production of such ointments involves pulverizing the leaves and boiling them with petrolatum. The mixture is filtered and placed in containers. Then, it is ready to use topically on the affected area of the body. The leaves have also been used to aromatize tobacco (Roig, 1974). This species has never been chemically or biologically evaluated. *Montanoa grandiflora* (*Eurycoma hartwegiana*) is known as the “daisy tree,” and its flowers are used ornamentally. This plant possesses a resinous fragrance, and in traditional Mayan medicine, the leaves are used to treat rheumatism (alone or as a poultice) and stomach aches (Méndez-González *et al.*, 2012). There are no reports

on the biological properties of this plant. Therefore, the aim of this investigation was to evaluate the anti-inflammatory activities of the polar (methanolic/acetonitrile) and non-polar (hexanic) extracts of these two plants that are traditionally used to alleviate symptoms of inflammation.

## METHODS

### Abbreviations

NO (nitric oxide), CA (*Critonia aromatisans*), MG (*Montanoa grandiflora*), MeOH (methanol), acn (acetonitrile), hx (hexane), DMSO (dimethyl sulfoxide), TPA (12-O-tetradecanoylphorbol-13-acetate), DMEM (Dulbecco's Modified Eagle Medium), MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), CAacn (MeOH/acn extract from *C. aromatisans*), CAhx (hx extract from *C. aromatisans*), MGacn (MeOH/acn extract from *M. grandiflora*), MGhx (Hexanic extract from *M. grandiflora*).

### Plant material

Leaves from *C. aromatisans* (871.2 g) and *M. grandiflora* (127.3 g) were collected from the botanical garden of the Traditional Medical Centre of Yaxcabá, Yucatán, México. at 1 km N of the road to "Libre Unión" town. Both species were collected in June 2010 and were identified by taxonomist professor Mendez-González. A voucher specimen of each plant was deposited at the Herbarium "Roger Orellana" of the Centro de Investigación Científica de Yucatán (CICY) under the collection numbers A. Dorantes 134 (*C. aromatisans*) and M. Méndez 1754 (*M. grandiflora*).

### Preparation of the extracts

Powdered leaves of the plants were extracted with methanol (MeOH) at room temperature (three times) to obtain the *C. aromatisans* (243 g) and *M. grandiflora* (21 g) MeOH extracts. A portion of each methanolic extract (1 g) was dissolved in MeOH, and then acetonitrile (acn) was added (1:3). This mixture was extracted with hexane, and then, both phases were separated to obtain the non-polar hexanic (CAhx and MGhx) and polar MeOH/acn fractions (CAacn and MGacn).

### In vitro assays

#### Isolation and cell culture of peritoneal macrophages

Macrophages were isolated from the peritoneal cavities of male ICR mice. Briefly, macrophages were harvested immediately by lavage with 10 mL of cold sterile PBS injected into the peritoneal cavity of each mouse, and the resultant exudates were immediately collected, washed two times with PBS, re-suspended and adjusted to  $1 \times 10^6$  cells/mL in Dulbecco's Modified Eagle's medium (DMEM) containing 10% inactivated foetal bovine serum, 100 U/mL penicillin and 100  $\mu$ L streptomycin (referred to as complete DMEM). Fifty-microliter aliquots of the cell suspension ( $5 \times 10^4$  cells/well) were cultured in 96-well plates with 200  $\mu$ L of complete DMEM for 24 h at 37°C in a humidified 5% CO<sub>2</sub> incubator. Non-adherent cells were removed by gentle washing with DMEM, and then, freshly prepared medium containing the plant extracts was added.

### Treatment of peritoneal macrophages

Purified peritoneal macrophages ( $5 \times 10^4$  cells/well) were incubated with the plant extracts at different concentrations (1, 10, 100, 500 and 1000  $\mu\text{g/mL}$ ). A control group treated with DMEM was included. The plates were maintained at  $37^\circ\text{C}$  in a humidified 5%  $\text{CO}_2$  incubator. After incubation, the supernatants were removed, and LPS (1  $\mu\text{g/mL}$ ) was added to the culture. The supernatants were collected after 72 h of LPS treatment for nitrite determination.

### Measurement of nitrite production

Nitrite production, an indicator of NO synthesis, was determined by the Griess reaction (Green, 1982). Briefly, 50  $\mu\text{L}$  of supernatant from each well of the 96-well plates were incubated with an equal volume of Griess reagent (1% sulphanilamide/0.1% naphthalene diamine dihydrochloride/2.5%  $\text{H}_3\text{PO}_4$ ) for 10 min at room temperature to quantify the level of nitrite (Ding, 1988). The absorbance was determined at 550 nm using a microplate reader. The relationship between the absorbance and the concentration of NO was determined using dilutions of sodium nitrite in culture medium with known concentrations (0-100  $\mu\text{M}$ ) as standards.

### Determination of cell viability

Cell viability was assessed using the mitochondrial-dependent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to purple formazan. Cells were obtained as described previously and were plated in a 96-well culture dish at a concentration of  $5 \times 10^4$  cells/well in complete DMEM. After an overnight incu-

bation, the cells were washed with DMEM, and subsequently, various concentrations of the tested extracts at 1, 10, 100, 500 and 1000  $\mu\text{g/mL}$  were added in a total volume of 200  $\mu\text{L}$  of medium. The cells were then cultured for 24 h at  $37^\circ\text{C}$  in a humidified 5%  $\text{CO}_2$  incubator. The supernatants were removed, and the cells were incubated with MTT (5  $\text{mg/mL}$  in PBS) for 4 h at  $37^\circ\text{C}$  and 5%  $\text{CO}_2$ . After this incubation, the formazan crystals formed were dissolved in DMSO. The extent of the reduction of MTT was quantitated by measuring the absorbance at 550 nm using a microplate reader. The proliferation percentage was calculated using the following equation:

$$\% \text{ proliferation} = (\text{OD sample} - \text{OD control} / \text{OD control}) \times 100$$

### In vivo assays

#### Animals

Male and female Balb/C mice (20-25 g) were purchased from the Animal Breeding laboratories of CIBO-IMSS (Guadalajara, Jalisco, Mexico). ICR mice (20-25 g) were provided from the Animal House of Centro de Investigaciones Regionales "Dr. Hideyo Noguchi"-UADY (Mérida, Yucatán, México). The animals were provided a standard pellet diet and water *ad libitum*. Five animals were used in each group. The animals were processed according to the ethical guidelines for Mexican procedures (Norma oficial Mexicana NOM-062-ZOO, 1999).

#### Preparation of test samples

Mice were weighed and then treated per os with 200  $\text{mg/kg}$  of extract previously dissolved in a solution of 5% Tween 80 in

water. The control group received 100  $\mu\text{L}$  of 5% Tween 80 in pure water and received the same experimental handling as the test groups. The anti-inflammatory drug indomethacin (10 mg/kg) was used as a positive control (Boughton-Smith, 1993).

### **Carrageenan-induced hind paw oedema in Balb/c mice**

The *in vivo* anti-inflammatory activity was evaluated using the carrageenan-induced hind paw oedema model with slight modifications (Winter, 1962). Briefly, four experimental groups and two control groups (positive and negative) were formed. Five Balb/c mice were included in each group and 30 min after the oral administration (200 mg/kg) of the test sample or vehicle, a suspension of carrageenan (Sigma, St. Louis, MO, USA) at 1% (0.25  $\mu\text{L}$ / paw) in sterile physiological saline solution (0.9%) was injected into the subplantar tissue of the right hind paw of each mouse. The thickness of the hind paw was measured before oral administration and 3 h after injection with carrageenan. The difference in footpad thickness was measured using a precision micrometer. The mean values of treated groups were compared with the mean values of the untreated control group (negative control), and the percentage inhibition of inflammation was calculated.

### **TPA-induced mouse ear oedema**

Four experimental groups and two control groups (positive and negative) were formed, with five Balb/c mice in each group. Briefly, 2.5  $\mu\text{g}$  of TPA (12-O-tetradecanoylphorbol-13-acetate) dissolved in 20  $\mu\text{L}$  of acetone was applied to each side of the right ear of each mouse in the experimental groups.

This thickness of the ear was measured before oral administration and 3 h after the TPA was applied. The difference in ear thickness was measured using a precision micrometer. The mean values of the treated groups were compared with the mean values of the untreated control group, and the percentage inhibition of inflammation was calculated.

### **Acute oral toxicity**

Acute oral toxicity was assessed in a short-term observation period of 72 h over morbidity and mortality of the animals (OECD, 2001). The mice were treated with a single dose of 200 mg/kg of the polar and non-polar extracts of *C. aromatisans* and *M. grandiflora*. The mice were observed for 4 h after the administration of the samples, paying special attention to the changes and alterations in behaviour and appearance of the fur. The observations were continued for 1 h each day. The following indicators of toxicity were assessed and recorded: breathing, pruritus, lethargy, appearance of the fur, excessive consumption of water, changes in eyes and mucous membranes, walking alterations, position, manipulation, drowsiness, self-cleanness, convulsions, salivation, diarrhoea, auto mutilation, coma and death.

### **GC-MS Analysis**

Preliminary analyses of the n-hexanic extracts were performed by gas chromatography/mass spectrometry with an Agilent technologies 6890N system equipped with an HP-5 MS capillary column (30 m  $\times$  25 mm  $\times$  0.25  $\mu\text{m}$ ). Helium was used as the carrier gas; the injection volume was one microliter, and the temperature program

used was as follows: 50°C (3 min); an initial temperature of 80°C (5 min.); an increase to 215°C at 4°C/min; and a hold at 215°C for 5 min. The identification of the components was based on the comparison of their mass spectra fragmentation with those reported in the NIST05 compounds library.

### Statistical analysis

For cell viability, experimental values are expressed as the mean  $\pm$  standard deviation of at least three experiments performed in triplicate. The data were analysed using one-way ANOVA with Dunnett's multiple comparisons test. For *in vivo* pharmacological evaluations, experiments were performed with five animals per group. For *in vivo* and *in vitro* tests, experimental values are expressed as the mean  $\pm$  standard error of the mean (S.E.M.). Statistical analysis was performed by one-way analysis of variance (ANOVA) with the Bonferroni post hoc test using PRISMA (GraphPad Software, San Diego, CA, version 5.01). In both cases,  $p \leq 0.05$  was used as the criterion for statistical significance (sample *vs.* control).

## RESULTS

### *In vitro* effects of *C. aromatisans* and *M. grandiflora* on NO production by mouse peritoneal macrophages

In the present study, it was observed that the extracts of *C. aromatisans* and *M. grandiflora* inhibited NO production in a concentration-dependent manner (fig. 1). The highest activity was found for the non-polar extract of *C. aromatisans* (CAhx). This extract almost completely inhibited NO production (97.58% inhibition) by pe-


ritoneal macrophages at the concentrations of 500 and 1000  $\mu\text{g/mL}$ . No effects on the viability of peritoneal macrophages exposed to different concentrations of extracts were observed, indicating the potential specificity of the extracts for NO production by macrophages

### Cell Viability

Cell viability was evaluated using the mitochondrial-dependent reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to purple formazan. It was showed that the treatments with 1, 10, 100, 500 and 1000  $\mu\text{g/mL}$  with the extracts did not alter the viability of mice peritoneal macrophages.

### *In vivo* anti-inflammatory effects

In the carrageenan-induced hind paw oedema model (table 1), the non-polar (CAhx) and polar extracts (CAacn) of *C. aromatisans* at the dose of 200 mg/kg resulted in the maximum inhibition (92 and 96%, respectively) of paw oedema at 3 h after carrageenan injection. Similar results were obtained for the TPA-Induced mouse ear oedema model (table 2), in which both extracts of *C. aromatisans* showed anti-inflammatory effects of up to 80% at the same dose. These effects were similar in both cases to the effects of the anti-inflammatory drug indomethacin. In contrast, the extracts obtained from *M. grandiflora* showed lower values of reduction of inflammation in the carrageenan-induced hind paw oedema model (table 2). In the TPA-induced mouse ear oedema model, no anti-inflammatory effect was observed for the non-polar or polar extract of *M. grandiflora* at the dose of 200 mg/kg.



**Fig. 1.** Effect of CAacn, CAhx (Fig. 1A) and MAacn, MGhx (Fig. 1B) on NO production after 72 h of activated mouse peritoneal macrophages. Control (-) represent non activated peritoneal macrophages. LPS represents activated peritoneal macrophages with LPS without extracts treatments. NO production by LPS activated peritoneal macrophages was significantly ( $*p < 0.05$ ) inhibited when different concentration (1, 10, 100, 500, 1000 µg/mL) of extracts were added. Data represent mean  $\pm$  S.D. values from the three independent experiments.



**Table 1.** Effects of the CAacn, CAhx, MGacn and MGhx extracts on carrageenan-induced hind paw oedema in mice.

	Group				
	Control	Indomethacin 10 mg/kg	CAacn	CAhx	MGhx
Hind paw oedema at 3 h ( $\times 10^{-2}$ mm) $\pm$ S.D.	44 $\pm$ 6.2	2.4 $\pm$ 1.6	1.8 $\pm$ 4.7*	3.6 $\pm$ 2.7*	23.3 $\pm$ 14*
Inflammation (%)	100	4.5	3.4	6.7	41.6

**Note:** Values are expressed as the mean  $\pm$  S.D. Statistically significant difference relative to the control group: \* $p < 0.05$  after one-way analysis of variance (ANOVA) with Bonferroni *post hoc test*. Untreated cells were used as a control in this evaluation.



**Table 2.** Effects of the CAacn, CAhx, MGacn and MGhx extracts on TPA-induced ear oedema in mice.

	Group				
	Control	Indomethacin 10 mg/kg	CAacn	CAhx	MGhx
Ear oedema at 3 h ( $\times 10^{-2}$ mm) $\pm$ S.D.	6.1 $\pm$ 2.2	2 $\pm$ 1.0	0.8 $\pm$ 1.5*	2.4 $\pm$ 0.5*	6.4 $\pm$ 2.6
Inflammation (%)	100	32.7	6.5	19.7	104.9

**Note:** Values are expressed as the mean  $\pm$  S.D. Statistically significant difference relative to the control group: \* $p < 0.05$  after one-way analysis of variance (ANOVA) with Bonferroni *post hoc test*. Untreated cells were used as a control in this evaluation.





## Acute toxicity

In the acute toxicity test, the four groups treated with the extracts of *C. aromatisans* and *M. grandiflora* showed no signs of adverse effects, abnormal behaviour, toxicity or lethality at the dose of 200 mg/kg 72 h after administration.

## GC-MS

Gas chromatography-mass spectrometry analysis of the non-polar extracts of *C. aromatisans* and *M. grandiflora* showed that they were primarily composed of fatty acids and terpenoids. *C. aromatisans* registered four major compounds at retention times (RT) of 7.51, 10.01, 10.94 and 20.57 min (Figure S1 in supplementary material) which included 2H-1-benzopyran-2-one, isolongifolen-5-one, methyl palmitate and Lup-20 (29)-en-3-ol, acetate, respectively. Other minor components were identified as ledol, 2-pentadecanone, stigmasterol, lupeol and  $\beta$ -sitosterol. *M. grandiflora* contained six main compounds at RT of 8.64, 17.17, 20.09, 20.49, 21.44 and 21.59 min (fig. S12 in supplementary material) with mass fragmentation pattern similar to caryophyllene oxide, hentriacontane, 12-Oleanen-3-yl acetate, Lup-20 (29)-en-3-ol, acetate. Compounds with retention times at 21.44 and 21.58 min were not found in the NIST library. Chromatography profiles and mass fragmentation patterns are included in the supplementary material as figures S1-S22.

## DISCUSSION

Different models were used to evaluate the anti-inflammatory effects of *C. aromatisans* and *M. grandiflora*. The *in vitro* experiments were performed using the ni-

tric oxide test. It is well known that during an inflammatory process, after signalling events, macrophages induce the expression of pro-inflammatory enzymes such as inducible nitric oxide synthase (iNOS). This enzyme is regulated by the secretion of pro-inflammatory cytokines and produces NO from L-arginine. Large amounts of NO can cause severe collateral damage in the tissue because NO can form peroxynitrite (ONOO-), a cytotoxic molecule related to inflammatory pathologies. For this reason, the regulation of the production of NO is an important target for inflammatory diseases (Guzik *et al.*, 2003).

The *in vivo* anti-inflammatory effects of the extracts were measured using the carrageenan-induced hind paw oedema and TPA-induced ear oedema models. These two models are well-known indicators of acute inflammation, and both evaluations can be performed at the same time because they use the same animals and the same treatment doses. In addition, both models allow the rapid evaluation of the effect of an extract or compound with potential anti-inflammatory properties. When the polysaccharide carrageenan is injected into the hind paw, it produces oedema mediated by white blood cells (neutrophils, monocytes and lymphocytes), major inflammatory mediators such as NO, prostaglandin E2 (PGE2) and the cytokines TNF- $\alpha$  and IL-6 (Kim, *et al.*, 2012). 12-O-tetradecanoylphorbol-13-acetate (TPA) is a topical oedematogenic agent and causes skin irritation and tumour promotion, because it stimulates PKC, which plays a critical role in signal transduction pathways and regulates cell growth and differentiation (Nishizuka, 1992). TPA affects the membrane, resulting in altered cell adhesion and the induction of arachidonic acid metabolism, specifically

causing the release of prostaglandins, which are responsible for oedema (Weinstein *et al.*, 1979). The results obtained in the present work, suggest that the different groups of anti-inflammatory metabolites of *C. aromatisans* are distributed between both polarities. Also, these results could indicate that the possible anti-inflammatory mechanism of MGhx (which showed an anti-inflammatory effect only in the carrageenan model) does not involve the PKC pathway. Further **in vitro** experiments can elucidate the specific anti-inflammatory mechanism of MGhx. A literature search for *C. aromatisans* did not find any previous chemical study. A previous study of *M. grandiflora* revealed the presence of limonene, citronella, camphene, pinene and phellandrene in essential oils prepared from the inflorescences, stems and leaves (Pérez-Amador *et al.*, 2006). The compound 6 $\beta$ -hydroxy-germacradien-8,12-olide (6-epi-desacetyl-laurenobiolide) was obtained from the chloroform extract of *M. grandiflora* (Quijano *et al.*, 1984). Different species of the Asteraceae family, including species of the genus *Eupatorium*, contain terpenoids, such as stigmasterol and taraxeryl acetate. Stigmasterol is able to reduce pro-inflammatory mediators such as NO and PGE2 in RAW 264.7 murine macrophages *in vitro* (Pandith *et al.*, 2013). Taraxeryl acetate reduces inflammation in *in vivo* models such as hind paw oedema induced by carrageenan and mouse ear oedema induced by TPA (Pérez-García *et al.*, 2005). In this preliminary evaluation of the non-polar extract of *C. aromatisans*, stigmasterol was found, but taraxeryl acetate was not. Stigmasterol has a known anti-inflammatory effect, and other components of the non-polar extract may contribute to this effect in a synergistic manner. In the *in vitro* evaluation, it was observed that

the extracts inhibited NO production in a concentration-dependent manner, and this activity might be responsible for their *in vivo* anti-inflammatory properties. However, considering that there exist different mediators that can be inhibited to produce the anti-inflammatory effect, further studies are necessary. The presence of terpenoids and fatty acids in the non-polar extracts could validate the use of this species in traditional medicine and the use of petrolatum to prepare the ointments. Because of its non-polar composition, petrolatum would retain the non-polar compounds and essential oils from the leaves, and then it can be administered topically. Due to these interesting results, the isolation and characterisation of the bioactive compounds in each plant are recommended. Based on the present work, it can be concluded that the non-polar and polar extracts of *C. aromatisans* and the non-polar extract of *M. grandiflora* possess *in vitro* and *in vivo* anti-inflammatory activities, and both species seem to be useful to treat inflammatory symptoms.

## CONCLUSION

The results obtained in the present study show fundamentals to validate the traditional uses by Mayan communities that endorse the use of this species to treat inflammation. Additionally, *C. aromatisans* has shown a stronger *in vivo* and *in vitro* activity, and one of the possible mechanisms of the anti-inflammatory response is the inhibition of the NO production.

## ACKNOWLEDGEMENTS

The authors thank to CONACyT [Grant number 201275] for providing us the funding support to perform this study. We

would also like to thank doctor Ivan Delgado from the University of Guadalajara, Jalisco, México, for the assistance with the animal management and care. We would also like to acknowledge Alfredo Dorantes for his support during sample collection and processing of the plant material.

## LITERATURE CITED

- Ahmed, N.A.; N.V. Christou, y J.L. Meakins, 1995. "The systemic inflammatory response syndrome and the critically ill surgical patient". *Current opinion in critical care*, **1**: 209.
- Azadmehr, A.; A. Afshari, B. Baradaran, R. Hajiaghvae, S. Rezazadeh, y H. Monsef-Esfahani, 2009. "Suppression of nitric oxide production in activated murine peritoneal macrophages in vitro and ex vivo by *Scrophularia striata* ethanolic extract". *Journal of Ethnopharmacology*, **124**: 166-169.
- Boughton-Smith, I.N.K., A.M. Deakin, R.L. Follenfant, B.J.R. Whittle, y L.G. Garland, 1993. "Role of oxygen radicals and arachidonic acid metabolites in the reverse passive Arthus reaction and carrageenin paw oedema in the rat". *British Journal of Pharmacology*, **110**: 896-902.
- Ding, A.H., C.F. Nathan, y D.J. Stuetz, 1988. "Release of reactive nitrogen intermediate and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production". *Journal of Immunology*, **141**: 2407-2412.
- Gallin, J.I, y R. Snyderman (Eds), 1999. *Inflammation: Basic Principles and Clinical Correlates*. 3rd. ed. Lippincott Williams & Wilkins Philadelphia, 1-4 pp.
- Green, L.C., D.A. Wagner, J. Glogowski, P.L. Skipper, J.J. Wishnok, y S.R. Tannebaum, 1982. "Analysis of nitrate, nitrite and (15 N) nitrate in biological fluids". *Analytical Biochemistry*, **126**: 131-138.
- Guzik, T.J., R. Korbust, y T. Adamek-Guzik, 2003. "Nitric oxide and superoxide in inflammation and immune regulation". *Journal of Physiology and Pharmacology*, **54**: 469-87.
- Jerzynska, J., P. Majak, A. Janas, R. Stelmach, W. Stelmach, K. Smejda, e I. Stelmach, 2014. "Predictive value of fractional nitric oxide in asthma diagnosis-subgroup analyses". *Nitric Oxide*, **40**: 87-91.
- Kim, D., D. Park, J. Kyung, Y.H. Yang, E.K. Choi1, Y.B. Lee, H.K. Kim, B.Y. Hwang, y Y.B. Kim, 2012. "Anti-inflammatory effects of Houttuyniacordata supercritical extract in carrageenan-air pouch inflammation model". *Laboratory Animal Research*, **28**(2): 137-140.
- Koeberle, A., y O. Werz, 2015. "Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation related disorders". *Biochemical Pharmacology*, **98**(1):1-15.
- MacMicking, J.; Q.W. Xie, y C. Nathan, 1995. "Nitric oxide and macrophage

- function". *Annual review of immunology*, **15**: 323-350.
- Méndez-González, M., R. Durán-García, R. Borges-Argáez, S. Peraza-Sánchez, A. Dorantes-Euan, J.L. Tapia-Muñoz, W. Torres-Aviles, y M. Ferrer-Cervantes, 2012. *Flora medicinal de los Mayas peninsulares. [Medicinal flora of peninsular Mayas]*. Centro de Investigación Científica de Yucatán, A.C., Fordecyt-Conacyt, Fomix, Pronatura Península de Yucatán Mérida, Yucatán, México, 81 pp.
- Nishizuka, Y., 1992. "Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C". *Science*, **258**: 607-614.
- Norma oficial Mexicana NOM-062-ZOO*. 1999. "Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio" [Technical specifications for production, care and use of laboratory animals] <http://www.senasica.gob.mx/?doc=743> [Consulted July 17, 2010].
- OECD. 2001. "Guideline for Testing of Chemicals: Acute Oral Toxicity-Acute Toxic Class Method". <http://www.oecd.org/chemicalsafety/risk-assessment/1948370.pdf> [Consulted July 17, 2010].
- Pandith, H.; X. Zhang, S. Thongpraditchote, Y. Wongkrajang, W. Gritsanapan, y S. Joon-Baek, 2013. "Effect of Siam weed extract and its bioactive component scutellarein tetramethyl ether on anti-inflammatory activity through NF- $\kappa$ B pathway". *Journal of Ethnopharmacology*, **147**: 434-441.
- Pérez-Amador, M.C.; V. Muñoz, y A. Noyola, 2006. "Essential oil and phytotoxic compounds in *Clibadium surinamens* L. and *Montanoa grandiflora* D.C. (Asteraceae)". *Revista Internacional de Botánica Experimental*, **75**: 145-150.
- Pérez-García, F.; E. Marin, T. Parella, T. Adzet, y S. Canigüeral, 2005. "Activity of taraxasteryl acetate on inflammation and heat shock protein synthesis". *Phytomedicine*, **12**: 278-284.
- Quijano, L.; J.S. Calderón, y G.F. Gómez, 1984. "The crystal structure of 6-epidesacetyl laurenobiolide, a germacra-1(10),4-diene-12,8 $\alpha$ -olide from *Montanoa grandiflora*". *Phytochemistry*, **23**(9): 1971-1974.
- Roig, J.T., 1974. *Plantas medicinales, aromáticas o venenosas de Cuba* [Medicinal plants, aromatic or poisonous]. Instituto del Libro, Habana, Cuba, 949 pp.
- Weinstein, I.B., L.S. Lee, P.B. Fisher, A. Mufson, y H. Yamasaki, 1979. "Action of phorbol esters in cell culture: mimicry of transformation, altered differentiation, and effects on cell membrane". *Journal of Supramolecular Structure*, **12**(2): 195-208.
- Wen-Jun, J.; I. Kan'ichiro, F. Megumi, T. Tomoko, K. Susumi, e I. Hiroshi, 2015. "Stereo-specific inhibition of nitric oxide production in macrophage

cells by flavononols: Synthesis and the structure-activity relationship". *Bioorganic & Medicinal Chemistry*, **23**(21): 6922-6929.

Zuther, J.E., 2009. *Lymphedema Management: The Comprehensive Guide for Practitioners*. 2nd. ed. Georg Thieme-verlag, Stuttgart Germany, 171 pp.

Winter, C.A.; E.A. Risley, y G.W. Nuss, 1962. "Carrageenan-induced oedema in hind paw of the rats as an assay for anti-inflammatory drugs". *Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine*, **111**: 544-547.

~~Guzik, T.J., R. Korbuet, y T. Adamek-Guzik, 2003. "Nitric oxide and superoxide in inflammation and immune regulation". *Journal of Physiology and Pharmacology*, **54**: 469-87.~~

Abundance






Fig. S1. Gas Chromatography profile of the n-hexanic extract of *C. aromatisans*.

Abundance




m/z→  
Abundance



m/z→


**Fig. S2.** Mass spectrum of compound at RT = 7.508 min and its similar mass spectrum pattern with 2H-1-Benzopyran-2-one (NIST library).

Abundance



m/z-&gt;

Abundance




m/z-&gt;

**Fig. S3.** Mass spectrum of compound at RT = 8.517 min and its similar mass spectrum pattern with 4aH-Cycloprop[e]azulen-4a-ol, decahydro-1,1,4,7-tetramethyl (NIST library)




Abundance




m/z-->

Abundance



m/z-->

**Fig. S4.** Mass spectrum of compound at RT=8.795 min and its similar mass spectrum pattern with Ledol (NIST library).



**Fig. S5.** Mass spectrum of compound at RT = 10.010 min and its similar mass spectrum pattern with isolongifolen-5-one (NIST library).






Fig. S6. Mass spectrum of compound at RT = 10.390 min and its similar mass spectrum pattern with 2-Pentadecanone (NIST library).



**Fig. S7.** Mass spectrum of compound at RT = 10.931 min and its similar mass spectrum pattern with Methyl palmitate (NIST library).






Fig. S8. Mass spectrum of compound at RT = 18.524 min and its similar mass spectrum pattern with Stigmasterol (NIST library).

Abundance





m/z-&gt;

Abundance




m/z-&gt;

**Fig. S9.** Mass spectrum of compound at RT = 18.934 min and its similar mass spectrum pattern with terol (NIST library).




**Fig. S10.** Mass spectrum of compound at RT = 19.665 min and its similar mass spectrum pattern with Lupeol (NIST library).



**Fig. S11.** Mass spectrum of compound at RT = 20.572 min and its similar mass spectrum pattern with Lup-20 (29)-en-3-ol, acetate (NIST library).




Abundance



Time-->

Fig. S12. Gas Chromatography profile of the n-hexanic extract of *M. glandiflora*.


Abundance



Time→


**Fig. S13.** Mass spectrum of compound at RT = 8.576 min and its similar mass spectrum pattern with 4H-Cycloprop [e]azulen-4-ol, decahydro-1,4,7-tetramethyl (NIST library).

Abundance



m/z-->


Abundance



m/z-->


**Fig. S14.** Mass spectrum of compound at RT = 8.634 min and its similar mass spectrum pattern with Caryophyllene oxide (NIST library).

Abundance



m/z-&gt;

Abundance



m/z-&gt;

**Fig. S15.** Mass spectrum of compound at RT = 11.356 min and its similar mass spectrum pattern with Hexadecanoic acid, ethyl ester (NIST library).






Fig. S16. Mass spectrum of compound at RT = 12.131 min and its similar mass spectrum pattern with Phytol (NIST library).

Abundance




m/z--&gt;

Abundance




m/z--&gt;

**Fig. S17.** Mass spectrum of compound at RT = 17.164 min and its similar mass spectrum pattern with Hentriacontane (NIST library).




**Fig. S18.** Mass spectrum of compound at RT = 20.075 min and its similar mass spectrum pattern with 12-Oleanen-3-yl acetate (NIST library).



**Fig. S19.** Mass spectrum of compound at RT = 20.485 min and its similar mass spectrum pattern with Lup-20 (29)-en-3-ol-acetate (NIST library).





**Fig. S20.** Mass spectrum of compound at RT = 20.572 min and its similar mass spectrum pattern with Taraxasterol (NIST library).




Fig. S21. Mass spectrum of compound at RT = 21.435 min.




Fig. S22. Mass spectrum of compound at RT = 21.582 min.